Results 251 to 260 of about 39,319 (333)

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). [PDF]

open access: yesCancer Chemother Pharmacol
Ouerdani A   +7 more
europepmc   +1 more source

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia [PDF]

open access: yes, 2015
Aymerich, Marta   +12 more
core   +1 more source

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. [PDF]

open access: yesBlood Adv
Chihara D   +19 more
europepmc   +1 more source

Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms. [PDF]

open access: yesClin Exp Med
Zhu N   +11 more
europepmc   +1 more source

Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies. [PDF]

open access: yesBMC Pharmacol Toxicol
Karimi MA   +10 more
europepmc   +1 more source

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

open access: gold, 2017
Benjamin J. Arthurs   +3 more
openalex   +1 more source

Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy. [PDF]

open access: yesExp Hematol Oncol
Zhu S   +9 more
europepmc   +1 more source

Ibrutinib-induced pyoderma gangrenosum

open access: yesPolish Archives of Internal Medicine, 2016
Andrzej Mital   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy